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Abstract
BCS1L encodes a homolog of the Saccharomyces cerevisiae bcs1 protein, which has a known role in the assembly of Complex III
of the mitochondrial respiratory chain. Phenotypes reported in association with pathogenic BCS1L variants include growth
retardation, aminoaciduria, cholestasis, iron overload, lactic acidosis and early death (GRACILE syndrome), and Björnstad
syndrome, characterized by abnormal flattening and twisting of hair shafts (pili torti) and hearing problems. Here we
describe two patients harbouring biallelic variants in BCS1L; the first with a heterozygous variant c.166C>T, p.(Arg56∗)
together with a novel heterozygous variant c.205C>T, p.(Arg69Cys) and a second patient with a novel homozygous c.325C>T,
p.(Arg109Trp) variant. The two patients presented with different phenotypes; the first patient presented as an adult with
aminoaciduria, seizures, bilateral sensorineural deafness and learning difficulties. The second patient was an infant who
presented with a classical GRACILE syndrome leading to death at 4 months of age. A decrease in BCS1L protein levels was
seen in both patients, and biochemical analysis of Complex III revealed normal respiratory chain enzyme activities in the
muscle of both patients. A decrease in Complex III assembly was detected in the adult patient’s muscle, whilst the paediatric
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patient displayed a combined mitochondrial respiratory chain defect in cultured fibroblasts. Yeast complementation studies
indicate that the two missense variants, c.205C>T, p.(Arg69Cys) and c.325C>T, p.(Arg109Trp), impair the respiratory capacity
of the cell. Together, these data support the pathogenicity of the novel BCS1L variants identified in our patients.
Introduction
Mitochondrial diseases encompass a heterogeneous group of
genetic defects characterized by a dysfunction in mitochon-
drial energy metabolism. Clinically, defects in the mitochondrial
oxidative phosphorylation (OXPHOS) system that consists of
four respiratory chain enzymes (CI-CIV) and the ATP synthase
(CV) manifest either within single organs or as multiorgan syn-
dromes. The involvement of both the nuclear andmitochondrial
genome in the build of the OXPHOS system underpins the varied
biochemical response and clinical heterogeneity seen in patients
with inheritedmitochondrial diseases. OXPHOS deficiencies can
be recognized as isolated events affecting individual respiratory
chain complexes, or more commonly occurring as combined
defects, usually affecting complexes containing mitochondrially
encoded OXPHOS subunits (CI, CIII, CIV and CV).
In comparison to single enzyme deficiencies associated with
Complex I and Complex IV caused by genetic defects in struc-
tural or accessory subunits, isolated Complex III defects are
relatively uncommon. The enzyme cytochrome bc1 or Complex
III is a central enzyme of the respiratory chain, catalyzing the
transfers of electrons from coenzyme Q to cytochrome c and
subsequently forcing protons to mitochondrial intermembrane
space via the Q cycle mechanism (1). Complex III functions as a
homodimer (CIII2) that consists of 11 polypeptide subunits, one
of which is encoded by the mitochondrial genome and remain-
ing 10 are nuclear encoded. Mutations in the mitochondrially
encoded structural subunit of Complex III, the cytochrome b
gene (MT-CYB), have been largely associated with isolated mito-
chondrialmyopathy and exercise intolerance.However, in recent
years, the wide use of next-generation sequencing (NGS) tech-
nologies enabled the discovery of a number of variants in nuclear
encoded mitochondrial Complex III structural subunits (CYC1,
UQCRB, UQCRQ, UQCRC2) and assembly factors (BCS1L, LYRM7,
TTC19, UQCC2, UQCC3) (reviewed in 2).
Pathogenic BCS1L gene variants are the most common cause
of Complex III deficiency, and to date, over 100 different variants
in BCS1L have been reported on ClinVar (https://www.ncbi.nlm.
nih.gov/clinvar/). The BCS1 homolog ubiquinol-cytochrome c
reductase complex chaperone (BCS1L) encodes for a highly
conserved yeast homolog of bcs1 that facilitates the last step of
Complex III assembly (3). BCS1L aids the insertion of the Rieske
Iron-Sulphur protein, encoded byUQCRFS1 into the pre-Complex
III2 dimer (Supplementary Material, Fig. S1). This is an essential
step in Complex III maturation and enables the enzyme to
become catalytically active. The spectrum of clinical phenotypes
that underlie BCS1L variants ranges from severe GRACILE
syndrome (growth retardation, aminoaciduria, cholestasis, iron
overload, lactic acidosis, early death) (4–6) to multisystemic
Complex III deficiency characterized by proximal tubulopathy,
liver failure and/or encephalopathy (7–9) and mild Björstand
syndrome with sensorineural hearing loss and brittle hair con-
dition known as pili torti (10). Understanding the pathogenicity
of different BCS1L variants has been challenging, and poor
phenotype-genotype correlations make it difficult to establish
a genetic diagnosis. Although it remains to be determined
why BCS1L variants exert such a varying spectrum of clinical
phenotypes, patterns in specific amino acid substitutions and
positioning within the BCS1L structure and tissue-specific
manifestation of BCS1L may provide additional clues on how
to improve phenotype-genotype correlations.
Here, we report two very different clinical cases of two unre-
lated patients with underlying pathogenic variants in the BCS1L
gene. The individual carrying the compound heterozygous vari-
ant c.166C>T, p.(Arg56∗) and c.205C>T, p.(Arg69Cys) in BCS1L
manifested with an adult-onset aminoaciduria and phospha-
turia consistent with a renal Fanconi syndrome, seizures, bilat-
eral sensorineural deafness and learning difficulties. In contrast,
the individual carrying a homozygous c.325C>T, p.(Arg109Trp)
variant presented with developmental delay, persistent lactic
acidosis, nephrocalcinosis, liver dysfunction and early death.
BCS1L protein levels were decreased in both patients, and the
activities of respiratory chain complexes were normal inmuscle.
A negative OXPHOS phenotype in the yeast bcs1L null mutant
was completely rescued by expressing the wild-type human
bcs1L gene, but not with the bcs1LR109W or bcs1LR69C mutant genes
mimicking the patients’ variants. These data provide functional
evidence that supports the pathogenic effects of the BCS1L vari-
ants identified in our patients.
Results
Clinical case reports
Patient 1. This white British man (Supplementary Material,
Fig. S2A), born to non-consanguineous parents, was referred
at the age of 32 years for the investigation of biochemical
disturbances including a metabolic acidosis, a raised serum
alkaline phosphatase and a low serum phosphate. He has
a significant past medical history of learning difficulties,
seizures and bilateral sensorineural deafness. Family history
revealed he had an older brother with a similar biochemical
phenotype, with established chronic kidney disease and who
also suffered from learning difficulties and epilepsy and died
following a seizure aged 39 years. On examination, he was
of slight build (height, 160 cm; weight, 44 kg; BMI, 17.4).
His blood pressure was normal. Urine dipstick confirmed
glycosuria (in the context of a normal blood glucose). Serum
and urine biochemistry showed hypophosphatemia and renal
phosphate wasting. He had established chronic kidney disease
and a mild metabolic acidosis. A screen for urinary amino
acids revealed a generalized aminoaciduria consistent with a
proximal tubulopathy and renal Fanconi syndrome. Table S1
shows his serum biochemistry alongside his brother’s for
comparison. The patient was treated with phosphate and low-
dose vitamin D supplementation. The patient remained well,
with good control of seizures and no unusual features. His
kidney function slowly declined over the subsequent years to
the present levels of serum creatinine (296 μmol/l) and eGFR
(20 ml/min/1.73m2) (CKD-EPI) at age 49 years (Supplementary
Material, Fig. S2B). On clinical examination at age 48 years,
he had low set ears, mild facial dysmorphism, normal eye
movements, pale optic discs but no obvious visual impairment.
He had spastic dysphonia and orofacial hyperkinesias. There
was no paresis, but he had tetraspasticity with increased
deep tendon reflexes with upgoing plantar reflexes on the
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Table 1. Clinical, molecular and biochemical features of patients carrying BCS1L variants
Patient 1 Patient 2
Age of onset/age at last follow-up 30 years/49 years Birth/4 monthsa
Sex Male Female
Family history Family 1—Unrelated parents, brother with
learning difficulties, epilepsy and chronic
kidney disease (deceased)
Family 2—Consanguineous parents, family
history of unexplained childhood death
Country of origin UK—Caucasian UK—Bangladeshi
Clinical presentations Learning difficulties, renal Fanconi syndrome
(including aminoaciduria, phosphaturia,
proximal renal tubular acidosis), epilepsy,
progressive chronic kidney disease, hearing
loss
Growth retardation, cholestasis, persistent
lactic acidosis, early death, developmental
delay, nephrocalcinosis
MRI scan Generalized involution N/A
BCS1L variantsb
Minor Allele Frequency (GnomADc and
ExAcd)
Compound Heterozygous
c.166C>T, p.(Arg56∗);
c.205C>T, p.(Arg69Cys)
0.0008824 and 0.0001895;
0.00006363 and 0.00005766
Homozygous
c.325C>T, p.(Arg109Trp);
c.325C>T, p.(Arg109Trp)
0.00004242 and 0.00006594
PolyPhen-2e Possibly damaging Possibly damaging
SIFTf Deleterious Deleterious
CADDg 31 31
CI-CIV respiratory enzyme activities Normal OXPHOS activities in muscle Normal OXPHOS activities in muscle
aAge at death.
bReference sequence NM_004328.4 and NP_004319.1.
cGenome Aggregation Database (gnomAD).
dExome Aggregation Consortium (ExAc).
ePolymorphism Phenotyping v2 (PolyPhen-2).
fSorting Intolerant From Tolerant (SIFT).
gCombined Annotation Dependent Depletion (CADD).
lower extremities. Romberg test result was negative, but he
had a spastic-ataxic gait. He had learning difficulties. Brain
MRI showed changes consistent with generalized involution
(Supplementary Material, Fig. S2C), and renal ultrasound scans
showed bilateral medullary nephrocalcinosis and a few small
cortical cysts.
Patient 2. This childwas born fromconsanguineous Bangladeshi
parents (first cousin marriage). Antenatally, fetal ultrasound
scans had identified both poor fetal growth (<5th centile)
and evidence of oligohydramnios. She was born at 36 weeks’
gestation by spontaneous vaginal delivery. APGAR scores were
9 at 1 minute and 9 at 5 minutes, and the birth weight was
1.3 kg. There was a notable family history of paternal twins
(aunt and uncle) dying within the first few weeks of life of
unknown cause and two paternal male cousins who had also
died at 2 weeks and 14 weeks of age of unknown cause. At
2 days after birth, the child was noted to be hypoglycaemic
with a raised anion-gap metabolic acidosis, with an elevated
serum lactate level (5.8 mmol/l) and a raised serum ammonia
level (173 μmol/l). Biochemical investigations revealed normal
acylcarnitine profile (excluding disorders of fatty acid and
branched-chain amino acid catabolism). Liver function was
abnormal with a conjugated hyperbilirubinemia. Treatment was
commenced, including sodium bicarbonate, Dalivit, vitamin
E and vitamin K. Thiamine, carnitine and alphacalcidol were
also given and the child stabilized, allowing discharge from
the neonatal unit at 43 days old. Genetic investigations were
initiated, and karyotyping showed chromosome 46XX with a
del (9) (q.21.12q21.2). Skin and muscle biopsies were performed
given a suspected mitochondrial disorder. Further episodes
of lactic acidosis and hypoglycaemia occurred aged 74 days.
Hyperinsulinism was identified and treated with oral diazoxide
and chlorothiazide. An abdominal ultrasound scan revealed
bilateral nephrocalcinosis and bone biochemistry showed an
elevated alkaline phosphatase, with a low PTH and serum
calcium. The girl deteriorated with a paralytic ileus and an acute
kidney injury from which she did not recover, and she died aged
4months of age. Unfortunately, no clinical details were available
for the affected male sibling of P2 who died soon after birth.
Molecular genetics diagnosis of BCS1L variants
In order to rule outmonogenic forms of renal Fanconi syndrome,
molecular genetic screening for variants in CLCN5, OCRL1 and
CTNS was initially performed in Patient 1 (P1). Subsequently,
the patient underwent whole genome sequencing, and bial-
lelic compound heterozygous variants in BCS1L c.166C>T,
p.(Arg56∗) (previously reported as pathogenic in 11) and
c.205C>T, p.(Arg69Cys) were identified (RefSeq NM_004328.4).
The minor allele frequency (MAF) for both variants p.(Arg56∗)
and p.(Arg69Cys) is less than 0.01, and in silico pathogenicity tools
predicted the c.205C>T, p.(Arg69Cys) variant to be pathogenic
(Table 1). Conflicting interpretations of pathogenicity have been
reported for the c.205C>T, p.(Arg69Cys) variant on ClinVar that
has been described as a variant of uncertain significance—likely
pathogenic (12).
Given the mitochondrial disease phenotype in Patient 2 (P2)
that appeared to have hallmarks of the GRACILE syndrome
associated with defects in BCS1L and abnormal liver function
previously concomitant with MPV17-related hepatocerebral
mitochondrial DNA depletion syndrome, candidate gene
sequencing for variants in BCS1L and MPV17 was performed
on genomic DNA isolated from P2. This identified homozygous
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missense variants c.325C>T,p.(Arg109Trp) (RefSeqNM_004328.4)
in the BCS1L gene. The affected male sibling of P2 also carried
the c.325C>T, p.(Arg109Trp) variant. The minor allele frequency
(MAF) was less than 0.01, and the c.325C>T,p.(Arg109Trp) variant
was predicted to by highly pathogenic (Table 1).
BCS1L variants were confirmed by Sanger sequencing
(Fig. 1A) and mapped to the N-terminal part of the BCS1L
protein (Fig. 1B). The parents of P1 (family 1) were deceased, and
therefore it was not possible to carry out segregation studies.
However, BCS1L mutation segregation analysis of P2 (family 2)
showed that both parents were heterozygous carriers for
c.325C>T, p.(Arg109Trp) variant (Fig. 1A).
Muscle histopathological diagnosis and
respiratory chain enzyme activities were
normal in BCS1L patients
Histopathological assessment of biopsied muscle tissue from
P1 was essentially normal. There was a slight increase in suc-
cinate dehydrogenase (SDH) and cytochrome c oxidase (COX)
activity around the periphery of some fibres (Fig. 1C). Gomori
trichrome staining suggested that subsarcolemmal accumula-
tions were present but not overtly ragged-red (Fig. 1C). Respira-
tory chain enzyme activities were measured in mitochondrial-
enriched muscle homogenates isolated from P1 and P2 skeletal
muscle as previously described (13). Mitochondrial respiratory
chain enzyme activities (Complexes I-IV) were within normal
range in both patients when compared to age-matched controls
(Fig. 1D).
Pathogenic variants in BCS1L cause loss of
BCS1L protein
Western blot analysis was carried out to assess the deleterious
nature of BCS1L variants present in P1 and P2. The steady-state
levels of BCS1L protein were diminished in lysates isolated from
skeletal muscle derived from P1 and fibroblasts of P2 when
compared to age-matched controls (Fig. 2A). The deleterious
impact of the identified genetic variants on BCS1L protein levels
strongly implies that these mutations adversely affect the sta-
bility of the protein.
The effect of BCS1L variants on the
steady-state levels of OXPHOS subunits and
complexes
To investigate the functional consequences of BCS1L variants
on steady-state levels of OXPHOS subunits and complexes, we
performed OXPHOS protein analysis on the available patient
fibroblasts and muscle samples. Immunoblotting analysis con-
firmed that the steady-state levels of all respiratory chain com-
plex subunits were relatively normal in fibroblasts derived from
P1when compared to controls (Fig. 2B). BCS1L has been shown to
facilitate the incorporation of the UQCRFS1 subunit into mature
Complex III (8) (Supplementary Material, Fig. S1). In order to
assess whether there were decreased amounts of fully assem-
bled Complex III in P1 fibroblasts, enriched mitochondrial mem-
brane extracts were separated by one-dimensional blue native
polyacrylamide gel electrophoresis (BN-PAGE) and mature Com-
plex III was immunodetected using antibodies against UQCRFS1,
whilst UQCRC2 antibodieswere used to detect bothmature Com-
plex III and the pre-Complex III enzyme lacking the UQCRFS1
subunit. Consistent with the SDS PAGE analysis of P1 fibroblasts,
the amounts of fully assembled Complex III and pre-Complex
III were relatively normal (Fig. 2C and Supplementary Material,
Fig. S3A). In addition, the amounts of OXPHOS Complexes I,
II, IV and V were analyzed, showing comparable levels to age-
matched control fibroblasts (Fig. 2C and Supplementary Mate-
rial, Fig. S3A). Conversely, the affected P2 fibroblasts displayed
a decrease in the steady-state levels of Complex III subunits
UQCRC2 and UQCRFS1 and the mitochondrially encoded COX1
and COX2 subunits of Complex IV (Fig. 2D). In addition, the
amounts of fully assembled Complex III enzyme immunode-
tected with the UQCRFS1 antibody showed a decrease in the
amounts of mature Complex III in P2 fibroblasts (Fig. 2C), whilst
there was a less marked assembly defect in Complex III when
using antibodies against the UQCRC2 subunit (Supplementary
Material, Fig. S3B). Interestingly, the amount of fully assem-
bled Complex IV holoenzymes was also decreased in P2 fibrob-
lasts (Fig. 2C), a finding consistent with the previously observed
reduction in levels of Complex IV subunits (Fig. 2D).
The OXPHOS protein analysis was also performed on skeletal
muscle homogenate that was available only from P1. West-
ern blotting demonstrated that the steady-state levels of the
Complex III subunit UQCRC2 were mildly decreased in muscle
homogenates isolated from P1 (Fig. 2E). There was a marked loss
of UQCRFS1 protein in both P1’s muscle (Fig. 2E) and P2’s fibrob-
lasts (Fig. 2D), supporting the role of BCS1L in the incorporation
of the Rieske Fe-S catalytic centre of Complex III. To assess the
OXPHOS complex assembly in P1’s skeletal muscle, mitochon-
drial membrane extracts were separated by one-dimensional
BN-PAGE. Consistent with the decreased levels of BCS1L and
Complex III subunits (Fig. 2E), the assembly of mature Com-
plex III was severely affected in muscle homogenates from P1
(Fig. 2F). In addition, the levels of both mature and pre-Complex
III detected by UQCRC2 were markedly decreased in P1 muscle
(Supplementary Material, Fig. S3C). The assembly of all the other
OXPHOS complexes was normal in P1 muscle (Fig. 2F). Together,
these data strongly suggest that there is a Complex III defect
present in skeletal muscle from P1 and a combined OXPHOS
defect in the fibroblasts of P2 affecting Complexes III and IV.
Analysis of morphological features of the
mitochondrial network in BCS1L patient
fibroblasts
Previous studies have reported abnormal mitochondrial mor-
phologies in paediatric patients carrying recessive BCS1L vari-
ants,where patient fibroblasts showed punctate or intermediate
mitochondrial tubules suggestive of a fragmentedmitochondrial
network (14). In order to assess the impact of BCS1Lmutations on
the mitochondrial network, confocal fluorescence microscopy
studies were performed on TMRM-stained age-matched control
and mutant BCS1L patient fibroblasts. As expected, both
paediatric and adult control fibroblasts displayed a normal
interconnected tubular mitochondrial network (Fig. 3). However,
the total mitochondrial network length was significantly greater
in P1 compared to adult control cells (Fig. 3A and Supplemen-
tary Material, Fig. S4A). In contrast, no marked differences
were observed in the average mitochondrial network length
between control and P2 fibroblasts harbouring the homozygous
p.(Arg109Trp) variant (Fig. 3B and Supplementary Material, Fig.
S4B). We hypothesize that the increased mitochondrial network
length present in the cells from P1, the adult patient, may be a
cell-protective compensatory mechanism that is active under
metabolic stress conditions. Indeed, previous studies have sug-
gested that mitochondrial hyperfusion is an important mecha-
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Figure 1. Molecular genetics, histochemical and biochemical studies of BCS1L patients. (A) Family pedigree analysis of patients carrying BCS1L variants and sequencing
chromatographs showing the compound heterozygous variants present in P1 c.166C>T, p.(Arg56∗) and c.205C>T, p.(Arg69Cys) and the homozygous variant c.325C>T,
p.(Arg109Trp) in P2 that segregated within the family. The probands are shown by an arrow, and BCS1L patient variants are indicated by an asterisk. (B) Schematic of
human BCS1L (GeneBank: NM_04328.4, 1663bp and NP_004319.1, 419 amino acids in length) denoting the position of the transmembrane domain (TMD), mitochondrial
import sequence (MTS), import auxiliary sequence (IAS) and the AAA-ATPase domain. The positions of BCS1L mutations reported in the present study are indicated.
Partial amino acid sequence alignments of BCS1L showing evolutionary conservation across different species. The human BCS1L variants are shaded in blue. (C)
Histochemical analysis of BCS1L patient’s skeletal muscle (P1) subjected to (i) haematoxylin & eosin and (ii) Gomori trichrome staining showing the presence of some
ragged-red fibres in the subsarcolemmal regions. Following (iii) SDH and (iv) sequential COX staining demonstrated relatively normal COX activity in P1 muscle. The
scale bar shown is 100 μm. Histochemical studies were not performed on P2. (D) Measurement of respiratory chain enzyme activities (CI-CIV) in mitochondria isolated
from skeletalmuscle of control (red) and BCS1L patients P1 (blue) and P2 (black).OXPHOS activitieswere normalized to themitochondrialmatrixmarker citrate synthase.
Mean enzyme activities shown for muscle controls (n=25) are set at 100%.
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Figure 2. Analysis of steady-state protein levels of BCS1L and OXPHOS subunits and complexes in fibroblasts and/or muscle derived from BCS1L patients.
(A) Immunoblotting of age-matched control (C1, C2) and patient (P1, P2) protein extracts against BCS1L, showing a decrease in the steady-state levels of BCS1L in
muscle from P1 and fibroblasts from P2. (B) SDS-PAGE analysis of whole cell lysates isolated from control and P1 fibroblasts. (C) One-dimensional BN-PAGE analysis
of DDM-solubilized mitochondrial membrane extracts of age-matched control and patient fibroblasts (P1, P2). (D) SDS-PAGE analysis was performed on whole cell
lysates isolated from control and P2 fibroblasts. Mitochondrial extracts from control and P1 skeletal muscle homogenates were subjected to immunoblotting analysis
of OXPHOS subunits and complexes following separation by (E) SDS-PAGE and (F) BN-PAGE, respectively. Muscle samples for P2 were not available for protein analysis.
(B-F) Immunoblotting was performed with antibodies against individual OXPHOS subunits as indicated, and the assembly of respiratory chain complexes was assessed
by using antibodies against NDUFB8 (Complex I), SDHA (Complex II), UQCRFS1 (Complex III), COX1 (Complex IV) and ATP5A (Complex V). In all, SDHA and/or SDHB were
used as loading controls.
nism for the maintenance of a homogenous mitochondrial con-
tent in order to preserve efficient ATP production and resistance
to apoptosis and autophagosomal degradation (15–17).
Yeast complementation studies
Next we performed complementation studies in a strain of S.
cerevisiae lacking the BCS1 gene (yeast ortholog of human BCS1L),
W303bcs1,which display anOXPHOS-negative phenotype char-
acterized by failure to grow in media containing obligatory aero-
bic compounds as the only carbon sources (18). The bcs1 strain
was transformed with wild-type and mutated human BCS1L or
bcs1LR69C and bcs1LR109W alleles cloned into the pYEX expression
vector. We first evaluated the oxidative growth by spot assay
analysis on SC medium supplemented with either glucose, glyc-
erol or ethanol. As previously observed, the OXPHOS-negative
phenotype could be rescued by expressing the wild-type human
BCS1L gene (7) but not the variant bcs1LR109W, whereas the
bcs1LR69C showed an intermediate phenotype (Fig. 4A).
To better define the oxidative growth deficiency, we
measured oxygen consumption, NADH-cytochrome c oxidore-
ductase (NCCR) and COX activity. The respiratory activity of
bcs1/hbcs1LR69C and bcs1/hbcs1LR109W was, respectively, ∼50%
or ∼80% less than that of parental strain (bcs1/hBCS1L) (Fig. 4B).
Moreover, the samemutant strains displayed a specific decrease
of Complex III activity (76% and 10% residual activity, respec-
tively), whereas Complex IV (cIV) activity was normal (Fig. 4C).
Together, these results support the pathogenicity of the two
novel BCS1L variants, p.(Arg69Cys) and p.(Arg109Trp) indicating
that they severely impaired the cells’ respiratory capacity.
Discussion
We present two patients with biallelic variants in BCS1L with
markedly different phenotypes.
The phenotype associated with P1 represents an intermedi-
ate between the very severe GRACILE syndrome and the much
milder Björnstad syndrome. The overlapping features included
a sensorineural deafness associated with a renal tubulopathy
syndrome aswell as learning difficulties and growth retardation.
BCS1L-related mitochondrial disease is a useful terminology to
describe patients like P1, which captures their broader pheno-
types. P1 did not display features of lactic acidosis, cholestasis
or iron overload. A noteworthy feature was the progressive
decline in renal function such that P1 is approaching end-stage
renal failure at the age of 49 years. It is likely that P1’s brother,
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Figure 3. Mitochondrial network analysis of BCS1L patients. Patient-derived and two independent control fibroblasts were incubated with TMRM and mitochondrial
network structural analysis was undertaken using MiNa on ImageJ. Mean network length was calculated, per cell, as a product of the mean branch length per cell and
mean number of branches per network. (A) P1 fibroblasts appeared significantly hyperfused compared to C1 (P=0.004), but not C2. (B) In contrast, P2 fibroblasts were
comparable to both control cells with regards to mean network size. Results represent data from three independent experiments (n≥ 30) and error bars represent S.E.M.
One-way ANOVA statistical analysis and post hoc Dunn’s comparison were performed, and significant P-values have been reported.
Figure 4. Complementation studies in yeast. (A) Oxidative growth phenotype. The strain bcs1 was transformed with pYEX-BX plasmid carrying the wild-type human
BCS1L, the mutated alleles bcs1LR69C and bcs1LR109W or the empty vector. Equal amounts of serial dilutions of cells from exponentially grown cultures (105, 104,
103, 102 cells) were spotted onto SC plates supplemented with 2% glucose, 2% glycerol or 2% ethanol. The growth was scored after 4 days of incubation at 28◦C.
(B) Oxygen consumption rates. Respiration was measured in cells grown in SC medium supplemented with 0.6% glucose at 28◦C. The values observed for the bcs1L
mutant cells are reported as a percentage of the respiration obtained in cells expressing the wild-type BCS1L gene. (C) NADH-cytochrome c oxidoreductase (NCCR)
(in black) and cytochrome c oxidase (cIV)–specific activities (in grey) were recorded on a mitochondrial-enriched fraction from cells grown at 28◦C in SC medium
supplemented with 2% lactate (bcs1/BCS1L and bcs1/bcs1LR69C) or 0.4% glucose and 2% lactate (bcs1/pYEXBX and bcs1/bcs1LR109W). Values were normalized
to that of BCS1L parental strain and represented as mean of at least two independent experiments.
who died before any genetic studies could be undertaken, was
also affected with biallelic BCS1L variants, given his similar
phenotype of chronic kidney disease, epilepsy and learning
difficulties. The renal failure seen in P1 (and perhaps his
brother) is likely to bemultifactorial, but will include progressive
nephrocalcinosis and likely tubulointerstitial damage secondary
to mitochondrial defects (19). Indeed the renal manifestations
of mitochondrial disorders are probably underrecognized and
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underestimated (20). P1 was of slight build. Previous reports have
identified five Pakistani patients diagnosed with a Tyr301Asp
variant in BCS1L affecting the AAA domain presenting with
Björnstad syndrome. All adult family members were of short
stature (152 cm, 156 cm and 161 cm) and weighing only 40 kg,
40 kg and 45 kg, respectively, with profound to severe hair loss
(age 64 years, 62 years and 57 years) (21). There are similarities
with P1 whose height and weight were 160 cm and 44 kg,
respectively, who also exhibited hair loss.
Biochemically, we did not detect a Complex III defect in the
muscle from P1; however, further analysis revealed a decrease
in the levels of Complex III subunits and mature Complex III
enzymes. Intriguingly, Finnish patients carrying the homozy-
gous missense variants p.(Ser78Gly) in BCS1L presenting with
a GRACILE syndrome had no detectable Complex III defect and
no neurological findings; however, these patients had increased
iron overload (6).
Here, we demonstrated that whilst BCS1L protein levels were
greatly decreased in muscle from P1, there was only a mild
decrease in the Complex III subunit UQCRC2 and the amount
of Complex III (Figs. 2E and Supplementary Material, Fig. 3C).
UQCRC2 is an early Complex III subunit and is likely to be
part of a more stable pre-Complex III subcomplex, which is still
detectable in P1muscle. Previous studies have shown that BCS1L
is required for the insertion of the Fe-S protein UQCRFS1 at the
final stages of Complex III assembly (Supplementary Material,
Fig. S1). Indeed,we observed a complete loss of UQCRFS1 protein
in P1 muscle homogenate and a marked CIII assembly defect
in P1 muscle (Figs. 2E and F). The absence of UQCRFS1 in P1
supports previous studies showing that BCS1L facilitates the
incorporation of the Fe-S protein into the pre-Complex III.
It is possible that the two variants present in P1 p.(Arg56∗) and
p.(Arg69Cys) affect different functions of BCS1L. The p.(Arg56∗)
variant has been previously identified in a British patient that
presented with Complex III deficiency and GRACILE syndrome
(aminoaciduria, hypotonia, seizures, increased lactate) accom-
panied by an early death at the age of 2 days. The second
variant p.(Val327Ala) identified in this patients resides in the
AAA ATPase domain of BCS1L and is likely to be causative alone
or in combination with the p.(Arg56∗) (6). Perhaps, P1 is more
stable due to a less deleterious nature of the p.(Arg69Cys), which
is supported by our yeast studies, where complementation with
a mutated human BCS1L allele hbcs1LR69C shows minor defect
when compared to the Δbcs1 null mutant.
In contrast to P1, P2 presented with a more classical GRACILE
syndrome. However, despite a more severe clinical phenotype,
Complex III enzyme activity in the muscle was normal (Fig. 1D).
Conversely, we were able to show an assembly defect in OXPHOS
complexes present in P2 fibroblasts, mildly affecting Complexes
III+ IV (Figs. 2C and D). Protein studies demonstrated BCS1L pro-
tein levelswere decreased on SDS and BN-PAGE andUQCRC2 and
UQCRFS1 levels were also decreased in patient fibroblasts. Inter-
estingly, it has been suggested that the failure to incorporate
the Fe-S protein into Complex III in yeast leads to instability of
nascent complexes and supercomplex formation (22). Multiple
OXPHOS defects have been observed in BCS1L-relatedmitochon-
drial disease (7,14). Combined OXPHOS deficiencies have been
previously reported particularly in patients with severe clinical
phenotypes. For instance, six Complex III-deficient patients have
been identified carrying a variety of BCS1L mutations, all of
whom died within 1 year of age (14). Furthermore, our yeast
complementation data support the fact that the p.(Arg109Trp)
variant produces a more severe biochemical phenotype explain-
ing the more severe clinical phenotype (Fig. 4).
There are presently no available structures of the BCS1L
N-terminal domain where the p.(Arg69Cys) and p.(Arg109Trp)
missense variants are located (within the import auxiliary
sequence) (Fig. 1B). Although a homology model of this domain
was recently reported (23), we were unable to confidently
replicate these results [a low (12.3 Å) resolution structure of
the 26S proteasome regulatory subunit 6A (PDB 6EPC) was
detected as a potential structural homologue using I-TASSER
software (24)]. The pathogenicity of the p.(Arg69Cys) and
p.(Arg109Trp) variants likely arise from the marked changes
in the physicochemical properties of these residues, with the
positively charged guanidinium group of arginine replaced
by the smaller polar cysteine or the larger (and rigid) non-
polar indole side-chain of tryptophan. Both p.(Arg69Cys)
and p.(Arg109Trp) mutations are likely to disrupt the local
protein environment, as well as neutralize potential stabilizing
interactions.
It is noteworthy that tissue-specific expression of BCS1L may
play a role in determining phenotypes (23). BCS1L is highly
expressed in a wide variety of tissues, and the tissue-specific
isoforms of BCS1L are likely to have an influence on the clinical
phenotype by affecting different developmental pathways and
tissue maintenance.
In conclusion, we have discovered and characterized new
clinical phenotypes associated with BCS1L variants, including
a patient with a BCS1L-related mitochondrial disease with pro-
gressive renal failure and a patient with a GRACILE syndrome
harbouring a novel BCS1L variant. Detailed mitochondrial stud-
ies were able to reveal defects that were absent onmuscle biopsy
and confirm the pathogenicity of the BCS1L variants. Our data
support the role of BCS1L in the incorporation of the Fe-S protein
into Complex III, affirming BCS1L as a candidate disease gene in
patients presenting without an obvious mitochondrial defect in
muscle. Patients presenting with GRACILE syndrome or BCS1L-
related mitochondrial disease phenotypes should be directly
screened for the presence of BCS1L variants, or BCS1L variants
identified by next-generation sequencing should be prioritized
for further investigation.
Materials and Methods
Written informed consent for diagnostic and research based
studies was obtained from the patient 1 (P1) and the family of
patient 2 (P2) in accordance with the Declaration of Helsinki pro-
tocols. Ethical approvals for P1 were obtained from the Northern
and Yorkshire Research Ethics Committee (09/H0903/36) and for
Genomics England from the HRA East of England—Cambridge
South Research Ethics Committee.
Genomic DNA/protein was extracted from peripheral-blood
lymphocytes, skeletal muscle and fibroblasts according to stan-
dard protocols.
Molecular genetics analysis
Following informed and written consent, blood samples were
obtained from P1 and P2, and DNAwas extracted using standard
methods. All methods were performed in accordance with the
relevant ethical guidelines and regulations. For P1, sequencing of
CLCN5,OCRL1 andCTNSwas performed byUKGTN.Whole exome
sequencing was performed by Genomics England via the 100000
genomes project. Confirmation of mutations was performed
using Sanger sequencing, using exon-specific primers. For P2,
candidate gene Sanger sequencing was performed for BCS1L and
MPV17.
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GnomAD (https://gnomad.broadinstitute.org/) and ExAC
(http://exac.broadinstitute.org/) external variant databases
were used for MAF analysis. PolyPhen-2 (http://genetics.
bwh.harvard.edu/pph2/), SIFT (http://sift.jcvi.org/) and CADD
(https://cadd.gs.washington.edu/) in silico pathogenicity tools
predicting missense variants were used. Candidate variants
were confirmed by Sanger sequencing.
Cell culture
Age-matched primary control and BCS1L patient fibroblast cell
lines were grown in high glucose Dulbecco’s modified Eagle’s
medium (Sigma) containing 10% fetal calf serum, 1× non-
essential amino acids, 50 U/ml penicillin, 50 μg/ml streptomycin
and 50 μg/ml uridine at 37◦C and 5% CO2 in a humidified
incubator.
Histochemical and biochemical analyses of
patient muscle
Cryo-sections of skeletal muscle biopsies (10 μm) undergone
standard diagnostic histochemical analyses according to
previously established procedures (25). The enzymatic activities
of individual mitochondrial respiratory chain complexes and
citrate synthase were determined spectrophotometrically in
enriched mitochondrial fractions isolated from control and
patient skeletal muscle homogenates (13).
Western blot and BN-PAGE analysis
Cellular protein extracts were prepared from control and patient
fibroblasts or skeletal muscle samples and analyzed by western
blotting as previously described in (26). Briefly, equal amounts
of protein lysates (30–40 μg) were resolved by 12% SDS polyacry-
lamide electrophoresis (PAGE) and subsequently transferred on
to polyvinyl difluoride (PVDF) membranes.
BN-PAGE analysis was performed to assess the steady-state
levels of individual OXPHOS complexes. Mitochondrial extracts
isolated from fibroblasts or skeletal muscle samples were solu-
bilized with n-dodecyl β-d-maltoside (DDM) as described previ-
ously (26). A total of 100 μg of mitochondrial membrane protein
extracts were separated by one dimensional 4% to 16% BN-PAGE
and then transferred onto PVDF membranes.
Immunoblotting was carried using primary antibodies
against: NDUFB8 (Abcam ab110242), SDHA (Abcam ab14715),
UQCRC2 (Abcam ab14745), COXI (Abcam ab14705), ATP5A
(Abcam ab14748), BCS1L (Abnova H00000617-M01), UQCRFS1
(Abcam 14746) and Total OXPHOS HumanWB Antibody Cocktail
(ab110411), followed by species appropriate HRP-conjugated
secondary antibodies (Dako). ECL-prime (GE Healthcare) and
BioRad ChemiDoc with Image Lab software were used for
detection.
Mitochondrial network analysis
Approximately 80 000 cells were seeded into 35 mm μ-Dishes
(Ibidi, 81 156) overnight. For mitochondrial network analysis,
cells were incubated for 30 minutes in 5 nm TMRM (Invitrogen,
T668). Facilitated by a 100× magnification oil immersion
objective, an inverted multipoint scanning iSim (VisiTech) with
a Ti-E microscope (Nikon) was used to capture Z-stack images of
individual cells (using a 590 l filter). Triplicate experiments were
undertaking using consistent microscope and laser settings
(n30 cells). Images underwent Richardson-Lucy deconvolution
(NIS Elements) before being processed on Fiji. Maximum
intensity projections were generated and analyzed using MiNA
(27). Total network length per cell was calculated by multiplying
mean branch length by mean number of branches per network.
Strains, media and generation of mutant
alleles
Yeast strains used in this workwereW303–1A:MATa ade2–1 leu2–
3112 ura3–1 his3–1 trp1–1 BCS1 and its isogenic bcs1::HIS3 (bcs1)
(18). Strains were grown in synthetic complete medium (SC)
media [0.69% yeast nitrogen base without amino acids (Formedi-
umTM, UK)] supplemented with 1 g/l drop-out mix according to
Kaiser et al. 1994 (28), except amino acids and bases necessary to
keep plasmids. Media were supplemented with various carbon
sources as indicated (Carlo Erba Reagents, Milan, Italy) in liquid
phase or after solidificationwith 20 g/l agar (FormediumTM,UK).
The bcs1R69C and bcs1R109W mutant alleles were generated with
the QuikChange II Site-Directed Mutagenesis Kit (Stratagene, La
Jolla, CA, USA), using BCS1L cDNA cloned in the pYEX plasmid
(8) as template DNA and the modified primers (base changes in
bold) as follows:
BCS1R69CFw: 5′-ggttgcttagctggctcacctgccacagtacccgtactcag-3′.
BCS1R69CRw: 5′-ctgagtacgggtactgtggcaggtgagccagctaagcaacc-3′.
BCS1R109WFw: 5′-ccattttatctggtattgggggaaatggattcgggtag
aacg-3′.
BCS1R109WRv: 5′-cgttctacccgaatccatttcccccaataccagataaa
atgg-3′.
After mutagenesis, sequences of inserts were verified by Sanger
sequencing, and the pYEX-BX/bcs1LR69C and pYEX-BX/bcs1LR109W
mutant constructswere used to transform thebcs1 yeast strain,
using the lithium acetate method (29).
Respiration measurement and biochemical
assay in yeast
Oxygen consumption was measured at 30◦C using a Clark-type
oxygen electrode (Oxygraph System Hansatech Instruments
England) according to (30). The activity of the respiratory
complexes NADH-cytochrome c oxidoreductase (NCCR) and
the COX (cIV) were measured spectrophotometrically on
a mitochondrial enriched fraction prepared as previously
described (31,32). Statistical analysis was performed through an
unpaired two-tailed t-test. Only P-values of less than 0.05 were
considered significant.
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